ESR1 and neoplasm: Treatment decisions in breast cancer patients are based on tumor predictive markers [estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2)], some of which are also prognostic markers (ER, PR, HER2, Ki-67).